Ligand Pharmaceuticals Expands Global License Agreement With CURx Pharmaceuticals, Inc.

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in expanding its global license agreement with CURx Pharmaceuticals, Inc. The agreement now includes the development and commercialization of Ligand’s Captisol-enabled Lamotrigine program. According to the terms of the expanded license, Ligand is eligible to receive $22 million in milestone payments.

CURx Pharmaceuticals develops therapeutics for chronic diseases. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Read the press release.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.